Antiviral drugs for influenza for 2023-2024.

IF 1.4 4区医学 Q4 PHARMACOLOGY & PHARMACY

Medical Letter on Drugs and Therapeutics Pub Date : 2023-11-13 DOI:10.58347/tml.2023.1689a

引用次数: 0

Abstract

Influenza is generally a self-limited illness, but pneumonia, respiratory failure, and death can occur, especially in patients at increased risk for influenza complications (see Table 1). Antiviral drugs recommended for treatment and chemoprophylaxis of influenza for the 2023-2024 season are listed in Table 2. Updated information on influenza activity and antiviral resistance is available from the CDC at www.cdc.gov/flu.

查看原文本刊更多论文

2023-2024年流感抗病毒药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Letter on Drugs and Therapeutics 医学-药学

CiteScore

1.00

自引率

42.10%

发文量

审稿时长

6-12 weeks

期刊介绍： The Medical Letter, Inc. is committed to providing objective, practical, and timely information on drugs and treatments of common diseases to help our readers make the best decisions for their patients—without the influence of the pharmaceutical industry. The Medical Letter On Drugs and Therapeutics is a biweekly publication that provides: Evidence-based, peer-reviewed evaluations of new FDA-approved drugs with conclusions reached by a consensus of experts New information on previously approved drugs including pivotal clinical trials, new indications, and safety warnings Consensus recommendations for the preferred and alternative treatments for common disorders Comparative reviews of drugs for a given indication with particular attention to clinical efficacy, adverse effects, drug interactions, and cost.